Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies

Read the full 243 word article

User Sign In